Cover Image
市場調查報告書

大腸癌的全球市場:產業分析與預測

Global Colorectal Cancer Market: Industry Analysis & Outlook 2021-2025

出版商 Koncept Analytics 商品編碼 549639
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
大腸癌的全球市場:產業分析與預測 Global Colorectal Cancer Market: Industry Analysis & Outlook 2021-2025
出版日期: 2017年08月21日 內容資訊: 英文 74 Pages
簡介

本報告提供大腸癌的全球市場調查,全球及美國、歐洲的市場趨勢,及疾病概要,對市場發展的各種影響要素分析,競爭環境,主要企業簡介等,總括性彙整。

第1章 概要

  • 大腸癌
  • 徵兆,症狀,階段
  • 診斷
  • 治療

第2章 大腸癌的全球市場

  • 癌症診斷的全球市場的預測(以金額為準)
  • 大腸癌篩檢受驗人數的預測
  • 大腸癌篩檢受驗人數的預測:各地區
  • 大腸癌篩檢產品市場
  • 服藥中的大腸癌患者數
  • 服藥中的大腸癌患者數:各地區
  • 服藥中的大腸癌患者數:各市場區隔
  • 大腸癌症治療藥市場
    • Modufolin的收益預測
    • Modufolin的收益預測:各市場區隔
    • 第一線藥物的Modufolin收益額
    • 第二線藥物的Modufolin收益額
    • 第三線藥物的Modufolin收益額

第3章 地區市場

  • 美國
    • 大腸癌篩檢受驗人數的預測
    • 大腸癌篩檢數:各試驗混合
    • C掃描保護蓋的收益預測
    • 第一線藥物服藥中的患者數
    • 第二線藥物服藥中的患者數
    • 第三線藥物服藥中的患者數
  • 歐洲
    • 大腸癌篩檢受驗人數的預測
    • C掃描保護蓋的收益預測
    • 第一線藥物服藥中的患者數
    • 第二線藥物服藥中的患者數
    • 第三線藥物服藥中的患者數

第4章 市場動態

  • 推動因素
    • 推動因素
    • 市場趨勢
    • 課題

第5章 競爭情形

  • 大腸癌的全球市場
    • 收益和市值比較
  • 大腸癌醫療藥的全球市場
    • 大腸癌症治療藥的全球市場:
  • 大腸癌篩檢的全球市場
    • DNA為基礎的大腸癌篩檢檢驗比較

第6章 企業簡介

目錄

Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine). A cancer is the abnormal growth of cells that has the ability to invade or spread to other parts of the body. Signs and symptoms for this cancer may include blood in the stool, a change in bowel movements, weight loss, and feeling tired all the time. The current screening regime for this disease comprises of gFOBT, FIT, flexible Sigmoidoscopy, Colonoscopy and others. Further, the treatment for CRC is limited to surgery, chemotherapy and radiotherapy or adjuvant therapies.

The global CRC market would be driven by factors such as rising geriatric population, better reimbursement policies, growing number of obese people and others. However, the dynamics such as stringent regulatory norms, side effects of therapies and high cost of screening tests or drugs are expected to act as a threat for market's growth. Rising awareness regarding the incidence of CRC and importance of diagnosis has propelled higher compliance with regular tests. Further, in order to harness the market potential, various companies are involved in developing lesser invasive and easy to use screening methods.

The report "Global Colorectal Cancer Market: Industry Analysis & Outlook (2021-2025)" provides a comprehensive study of global market and also major regional markets. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in-depth. The global market is highly competitive consisting of several large enterprises including Bayer AG, Roche Holding AG, Merck & Co., Inc. and Eli Lilly and Company. The competitive landscape of the respective market, along with the company profiles of leading players are discussed in detail.

Table of Contents

1. Overview

  • 1.1 Colorectal Cancer
  • 1.2 Signs, Symptoms and Stages
  • 1.3 Diagnosis
  • 1.4 Treatment

2. Global Colorectal Cancer Market

  • 2.1 Global Cancer Diagnostics Market Forecast by Value
  • 2.2 Global CRC Screening Patient Volume Forecast
  • 2.3 Global CRC Screening Patient Volume by Region
  • 2.4 Global CRC Screening Product Market
    • 2.4.1 Global C-Scan Cap Revenue Forecast
  • 2.5 Global CRC Patients on Drugs by Volume
  • 2.6 Global CRC Patients on Drugs by Region
  • 2.7 Global CRC Patients on Drugs by Segments
  • 2.8 Global CRC Drug Market
    • 2.8.1 Global Modufolin Revenue Forecast
    • 2.8.2 Global Modufolin Revenue Forecast by Segments
    • 2.8.3 Global Modufolin Revenue as First Line Drug
    • 2.8.4 Global Modufolin Revenue as Second Line Drug
    • 2.8.5 Global Modufolin Revenue as Third Line Drug

3. Regional Market

  • 3.1 The US
    • 3.1.1 The US CRC Screening Patient Volume Forecast
    • 3.1.2 The US CRC Screening Volume by Test Mix
    • 3.1.3 The US C-Scan Cap Revenue Forecast
    • 3.1.4 The US Patients on First Line CRC Drug by Volume
    • 3.1.5 The US Patients on Second Line CRC Drug by Volume
    • 3.1.6 The US Patients on Third Line CRC Drug by Volume
  • 3.2 Europe
    • 3.2.1 Europe CRC Screening Patient Volume Forecast
    • 3.2.2 Europe C-Scan Cap Revenue Forecast
    • 3.2.3 Europe Patients on First Line CRC Drug by Volume
    • 3.2.4 Europe Patients on Second Line CRC Drug by Volume
    • 3.2.5 Europe Patients on Third Line CRC Drug by Volume

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Growing Geriatric Population
    • 4.1.2 Rising Healthcare Expenditure
    • 4.1.3 Growing Global GDP per Capita
    • 4.1.4 Surging Obese Population
    • 4.1.5 Rising Awareness Regarding CRC
  • 4.2 Key Trends & Development
    • 4.2.1 Rising Compliance to CRC Screening
    • 4.2.2 Development of New CRC Drugs
  • 4.3 Challenges
    • 4.3.1 High Cost of Screening and Drugs
    • 4.3.2 Side Effects of Drugs
    • 4.3.3 Stringent Drug Approval Process

5. Competitive Landscape

  • 5.1 Global CRC Market
    • 5.1.1 Revenue and Market Cap. Comparison
  • 5.2 Global CRC Drugs Market
    • 5.1.2 Global CRC Drugs Market by Company Share
  • 5.3 Global CRC Screening Market
    • 5.3.1 DNA based CRC Screening Tests Comparison

6. Company Profiles

  • 6.1 Bayer AG
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 Roche Holding AG
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 Merck & Co., Inc.
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 Eli Lilly and Company
    • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies

List of Charts

  • Stages of Colorectal Cancer
  • Treatment Option for Colorectal Cancer
  • Global Cancer Diagnostics Market Forecast by Value (2021-2025)
  • Global CRC Screening Patient Volume Forecast (2021-2025)
  • Global CRC Screening Patient Volume by Region (2021)
  • Global C-Scan Cap Revenue Forecast (2021-2025)
  • Global CRC Patients on Drugs by Volume (2021-2025)
  • Global CRC Patients on Drugs by Region (2021)
  • Global CRC Patients on Drugs by Segments (2021)
  • Global Modufolin Revenue Forecast by Value (2021-2025)
  • Global Modufolin Revenue Forecast by Segments (2021/2025)
  • Global Modufolin Revenue as First Line Drug (2021-2025)
  • Global Modufolin Revenue as Second Line Drug (2021-2025)
  • Global Modufolin Revenue as Third Line Drug (2023-2025)
  • The US CRC Screening Patient Volume Forecast (2021-2025)
  • The US CRC Screening Volume by Test Mix (2016)
  • The US C-Scan Cap Revenue Forecast (2021-2025)
  • The US Patients on First Line CRC Drug by Volume (2021-2025)
  • The US Patients on Second Line CRC Drug by Volume (2021-2025)
  • The US Patients on Third Line CRC Drug by Volume (2021-2025)
  • Europe CRC Screening Patient Volume Forecast (2021-2025)
  • Europe C-Scan Cap Revenue Forecast (2021-2025)
  • Europe Patients on First Line CRC Drug by Volume (2021-2025)
  • Europe Patients on Second Line CRC Drug by Volume (2021-2025)
  • Europe Patients on Third Line CRC Drug by Volume (2021-2025)
  • Global Geriatric Population (2012-2016)
  • Global Healthcare Expenditure Per Capita (2012-2016)
  • Global GDP Per Capita (2012-2016)
  • Global Obese Population (2012-2016)
  • Percentage of Adults in Compliance in the US (2012-2016)
  • Number of New CRC Drugs under Pipeline (2016)
  • Drug Approval Process
  • Global CRC Drugs Market by Company Share (2016)
  • DNA based CRC Screening Tests Comparison (2016)
  • Bayer AG Net Sales by Segment (2016)
  • Bayer AG Net Sales and Net Income (2012-2016)
  • Bayer AG R&D Expenditure (2014-2016)
  • Roche Holding AG Sales by Segment (2016)
  • Roche Holding AG Sales and Net Income (2012-2016)
  • Roche Holding AG R&D Expenditure (2014-2016)
  • Merck & Co., Inc. Sales by Segment (2016)
  • Merck & Co., Inc.'s Sales and Net Income (2012-2016)
  • Merck & Co., Inc.'s R&D Expenditure (2014-2016)
  • Eli Lilly and Company Revenue by Segment (2016)
  • Eli Lilly and Company Revenue and Net Income (2012-2016)
  • Eli Lilly and Company R&D Expenditure (2014-2016)

List of Tables

  • Revenue and Market Cap. Comparison (2016)
  • DNA based CRC Screening Tests Comparison (2016)
  • Allergan Plc. Body Contouring Key Product Comparison (2017)
  • Number of Products in Pipeline by Segments (2016)
Back to Top